Intervention not reported
Stroke (non‐fatal) · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention probably leads to lower stroke (non‐fatal) (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · patients with acute coronary syndrome
Statins showed no clear difference in fatal and non‐fatal stroke compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Fatal and non‐fatal stroke ( · people with or at risk of cardiovascular disease
The intervention showed no clear difference in fatal and non‐fatal stroke ( (low certainty).
1 finding from 1 review
Fatal and non‐fatal ischaemic stroke · people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease or at high risk of atherothrombotic disease
clopidogrel plus aspirin probably leads to lower fatal and non‐fatal ischaemic stroke compared with aspirin alone (moderate certainty).
1 finding from 1 review
Stroke · middle‐aged US male physicians
Vitamin C supplementation showed no clear difference in total stroke (fatal and non‐fatal) Physicians compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Combined CVD death, non‐fatal MI, or non‐fatal stroke · patients in primary prevention of cardiovascular disease events
The intervention probably leads to lower combined CVD death, non‐fatal MI, or non‐fatal stroke (moderate certainty).
1 finding from 1 review
Intervention not reported
ASCVD event, such as fatal or non‐fatal myocardial infarction or stroke. Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
The intervention showed no clear difference in ASCVD event, such as fatal or non‐fatal myocardial infarction or… (low certainty).
1 finding from 1 review
Clinical CVD events (CVD mortality, non‐fatal MI and stroke, revascularisations) · people at high risk of or withcardiovascular disease
Transcendental meditation (TM) showed no clear difference in clinical CVD events (CVD mortality, non‐fatal MI and stroke,… compared with active comparators (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke
Fibrates showed no clear difference in stroke (ischaemic or haemorrhagic, non‐fatal or fatal) during the… compared with control (low certainty).
2 findings from 1 review
Stroke, myocardial infarction, or vascular death · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke
Fibrates probably leads to lower composite outcome of non‐fatal stroke, non‐fatal myocardial… compared with control (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · adults with or without existing CVD
It is very uncertain whether higher changes stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Combined outcome of non‐fatal myocardial infarction, non‐fatal stroke, and total number of deaths · patients with acute coronary syndrome
Statins showed no clear difference in combined outcome of non‐fatal myocardial infarction, non‐fatal… compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Composite outcome of non‐fatal stroke, non‐fatal myocardial infarction, and vascular death without clofibrate · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke
Fibrates showed no clear difference in composite outcome of non‐fatal stroke, non‐fatal myocardial… compared with control (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients with heart failure with sinus rhythm
Summary of findings: warfarin showed no clear difference in non‐fatal cardiovascular events (non‐fatal stroke, myocardial… compared with aspirin (moderate certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · patients with heart failure with sinus rhythm
Summary of findings: warfarin showed no clear difference in non‐fatal cardiovascular events (non‐fatal stroke, myocardial… compared with clopidogrel (low certainty).
1 finding from 1 review
Composite endpoint (including all‐cause mortality, non‐fatal myocardial infarction and/or any new stroke assessed at 30 days after surgery) · people undergoing CABG (with or without valve surgery)
RIPC showed no clear difference in composite endpoint (including all‐cause mortality, non‐fatal… compared with no RIPC (moderate certainty).
1 finding from 1 review